Texas-based Kimberly-Clark Corp. will acquire Kenvue Inc., the New Jersey-based manufacturer of Tylenol, the companies ...

Kimberly-Clark announced it will acquire Summit-based Kenvue in a cash and stock transaction valued at $48.7 billion. The ...

Kimberly-Clark Corporation , a global personal care leader, and Kenvue Inc. , a global consumer health leader, today announced an agreement under which Kimberly-Clark will acquire all of the ...

Kimberly-Clark is committed to maintaining a robust credit profile ... Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2 share positions in approximately 70 countries. Our company's ...

The deal is expected to close in the second half of next year. It still needs approval from shareholders of both both ...

Kleenex and Cottonelle maker Kimberly-Clark said it's buying Tylenol maker Kenvue in a $48.7 billion deal. Kenvue ( KVUE) ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

Mike Hsu aims to stoke the consumer company’s growth by veering into Kenvue’s higher-margin but risky health products.

IP, M&A, life sciences and competition partners advised on deal that brings together brands such as ‘Huggies’ and ‘Kleenex’ ...

One of biggest takeovers so far this year will create a global company with annual revenues of roughly $32 billion.

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?